Aptevo End Period Cash Flow from 2010 to 2024

APVO Stock  USD 0.34  0.03  9.68%   
Aptevo Therapeutics End Period Cash Flow yearly trend continues to be very stable with very little volatility. End Period Cash Flow is likely to grow to about 23.3 M this year. During the period from 2010 to 2024, Aptevo Therapeutics End Period Cash Flow quarterly data regression pattern had sample variance of 231.1 T and median of  9,676,000. View All Fundamentals
 
End Period Cash Flow  
First Reported
2014-12-31
Previous Quarter
8.1 M
Current Value
7.8 M
Quarterly Volatility
18.1 M
 
Yuan Drop
 
Covid
Check Aptevo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aptevo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 538.6 K, Interest Expense of 43.1 M or Selling General Administrative of 19.2 M, as well as many indicators such as Price To Sales Ratio of 4.17, Dividend Yield of 0.0 or PTB Ratio of 0.16. Aptevo financial statements analysis is a perfect complement when working with Aptevo Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Aptevo Therapeutics Correlation against competitors.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.

Latest Aptevo Therapeutics' End Period Cash Flow Growth Pattern

Below is the plot of the End Period Cash Flow of Aptevo Therapeutics over the last few years. It is Aptevo Therapeutics' End Period Cash Flow historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Aptevo Therapeutics' overall financial position and show how it may be relating to other accounts over time.
End Period Cash Flow10 Years Trend
Slightly volatile
   End Period Cash Flow   
       Timeline  

Aptevo End Period Cash Flow Regression Statistics

Arithmetic Mean16,602,251
Geometric Mean10,640,458
Coefficient Of Variation91.57
Mean Deviation12,459,335
Median9,676,000
Standard Deviation15,202,626
Sample Variance231.1T
Range42.7M
R-Value0.69
Mean Square Error129.4T
R-Squared0.48
Significance0
Slope2,355,005
Total Sum of Squares3235.7T

Aptevo End Period Cash Flow History

202423.3 M
202316.9 M
202222.6 M
202146.3 M
202042.5 M
201919.9 M
201838.1 M

About Aptevo Therapeutics Financial Statements

Aptevo Therapeutics investors utilize fundamental indicators, such as End Period Cash Flow, to predict how Aptevo Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
End Period Cash Flow16.9 M23.3 M

Pair Trading with Aptevo Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aptevo Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aptevo Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against Aptevo Stock

  0.43KZR Kezar Life SciencesPairCorr
  0.34A Agilent Technologies Sell-off TrendPairCorr
The ability to find closely correlated positions to Aptevo Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aptevo Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aptevo Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aptevo Therapeutics to buy it.
The correlation of Aptevo Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aptevo Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aptevo Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Aptevo Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Aptevo Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aptevo Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aptevo Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aptevo Therapeutics Stock:
Check out the analysis of Aptevo Therapeutics Correlation against competitors.
To learn how to invest in Aptevo Stock, please use our How to Invest in Aptevo Therapeutics guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aptevo Therapeutics. If investors know Aptevo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aptevo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.24)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.73)
Return On Equity
(2.51)
The market value of Aptevo Therapeutics is measured differently than its book value, which is the value of Aptevo that is recorded on the company's balance sheet. Investors also form their own opinion of Aptevo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aptevo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aptevo Therapeutics' market value can be influenced by many factors that don't directly affect Aptevo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aptevo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aptevo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aptevo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.